Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

(1.06)Shares used in computing net loss
per share - basic and diluted

146,280144,033145,730143,525A reconciliation of reported GAAP operating net loss to non-GAAP operating income (loss) excluding non-cash items is provided in the tables that follow (in thousands, unaudited):Quarter ended
December 31, Twelve months ended
December 31, 2011201020112010GAAP operating loss

$ (429,754)$  (10,309)$ (491,459)$  (126,744) Revenue sharing obligation
  note payments on
  net BYETTA sales (1)

(6,088)-(6,088)- Stock-based compensation

9,1948,78832,47236,022 Other non-cash compensation

3,6134,10416,52719,735 Depreciation and amortization

10,50714,89247,37357,335 Amortization of deferred revenue and other credits

(3,141)(1,875)(11,930)(7,500) Net costs to reacquire economic
  interest in exenatide products (1)

431,587-431,587- Restructuring

1,7077,3287,19016,780Non-GAAP operating income (loss)

$  17,625$
22,928$   25,672$   (4,372)Quarter endedDecember 31,Twelve months endedDecember 31,2011201020112010GAAP net loss

$ (461,471)$  (19,183)$ (543,399)$  (152,314) Revenue sharing obligation note payments on  net BYETTA sales (1)

(6,088)-(6,088)- Stock-based compensation

9,1948,78832,47236,022 Other non-cash compensation

3,6134,10416,52719,735 Depreciation and amortization

10,50715,41747,37357,335 Amortization of deferred revenueand other credits

(3,141)(2,400)(11,930)(7,500) Net costs to reacquire economic
interest in exenatide products (1)

431,587-431,587- Restructuring

1,7077,3287,19016,780Interest expense, net

11,7634,65823,9789,002Loss on fair value adjustments

15,751-15,751-Non-GAAP net income (loss)

$  13,422$
8,712$   13,461$   (20,940)Non-GAAP net income (loss) per shareBasic

$ 0.09$ 0.13$ 0.09$  (0.15)Dil
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Calif., June 2, 2011 DURECT Corporation (Nasdaq: ... Chief Medical Officer and Executive Vice President, Corporate Strategy ... opportunities.  Dr. Stauffer and DURECT have entered into a ... (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) "We appreciate all ...
... SAN DIEGO, June 2, 2011 Biocept, Inc. today ... a poster at the 2011 Annual Meeting of the ... Chicago, Illinois June 3-7. The poster presentation is based ... logy C ell E nrichment and ...
Cached Medicine Technology:DURECT Announces Resignation of Chief Medical Officer 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 3
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... Dr. Steven Shoshany of New ... , to coincide with an exciting new direction he is taking with his office and an ... New York ... in New York City for more than 13 years in his SOHO office. He recently launched ...
... ... , ... Ind. (Vocus) June 23, 2009 -- Press Ganey Associates, Inc., the health care industry,s ... Patient Perspectives on American Health Care., According to the report, patients now spend an ...
... CetylMax, LLC and Flexadren, LLC, manufacturers and distributors of ... aiding in joint support and pain relief, announced today ... Celadrin, did not prevail in its claims against CetylMax(R) ... the Federal litigation between CetylMax(R) and Flexadren(R) and Imagenetix. ...
... With yet another tragedy in the headlines, Pennsylvania residents ... residents of our state,s assisted living facilities. , ... such as those that forced the Department of Public ... , , Earlier this month, an aide at ...
... June 22 Providence Tarzana Medical Center on Friday ... generation in imaging - the Ziehm Vision RFD - in this ... of a patient who had suffered a small stroke. , ... staff at Tarzana, liked what he saw in the crystal-clear image ...
... Seabrook House is proud to announce their sponsorship of "How ... Lamm, BRI-I, CAI. , , Founder of Intervention ... a nationally recognized Board-Registered Interventionist, Brad Lamm BRI-I, CAI, will ... 2009 at 6:30pm at The Radnor in St. Davids, PA ...
Cached Medicine News:Health News:New York City Chiropractor Announces New State-Of-The-Art Facility, Website 2Health News:Patients Spent an Average of Four Hours and Three Minutes in U.S. Emergency Departments in 2008, According to Latest Press Ganey Report 2Health News:Patients Spent an Average of Four Hours and Three Minutes in U.S. Emergency Departments in 2008, According to Latest Press Ganey Report 3Health News:Patients Spent an Average of Four Hours and Three Minutes in U.S. Emergency Departments in 2008, According to Latest Press Ganey Report 4Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 2Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 3Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 2Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 3Health News:Providence Tarzana Surgeon First in U.S. to Use New State-of-the-Art Imaging Tool 2Health News:'How to Change Someone You Love' Offers Help to Those Who Feel Powerless in the Face of Addiction 2
... In the specialty areas of ... intensive care work, it is ... your practice. Alokas motorized TEE ... and Tissue Harmonic Echo technology ...
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: